Sensus Healthcare and Texas Dermatology Associates at Baylor University Medical Center Announce the Formation of the SRT Universityâ„¢ Comprehensive Education Series for Practitioners, Healthcare Professionals, and Patients
BOCA RATON, Fla., May 18, 2012 /- Sensus Healthcare and Texas Dermatology Associates at Baylor University Medical Center of Dallas, TX are proud to announce the establishment of the SRT University™ Comprehensive Education Series for practitioners, healthcare professionals, and patients. SRT University™ will offer multi-tiered education and training curriculums for...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
ALLEGAN, Mich., May 18, 2012 /- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Lansoprazole capsules (15 mg). Shipments of product to customers have already begun. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ) Thi...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Richard Wolf Medical Instruments introduces groundbreaking 5514 Endocam Performance HD
VERNON HILLS, Ill., May 18, 2012 /- Surgeons using endoscopy to stalk pathology know that sharper views enhance treatments and improve patients' outcomes. But until now, high-definition endocams have been too expensive for many physicians in private offices or ambulatory surgery centers. (Logo: http://photos.prnewswire.com/prnh/20120426/CG95191LOGO ) Richard Wolf Medical...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Consumers Are Advised to Be Aware of Hidden Costs in Some Discount Dental Plans
SAN DIEGO, Calif., May 18, 2012 /- Not all discount dental plans are created equal, according to Dr. Michael Grossman, President and CEO at First Dental Health . Unexpected fees totaling hundreds of dollars are common and can take consumers by surprise. In addition, some discount dental plan specialists' fee discounts are very limited and difficult to verify, and not all plan...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Digestive Care, Inc. Announces FDA Approval of PERTZYEâ„¢ (pancrelipase) Delayed-Release Capsules
BETHLEHEM, Pa., May 18, 2012 /- Digestive Care, Inc. (DCI), announced that the company has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for PERTZYE™, indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. PERTZYE is a unique pancreatic enzym...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
NATICK, Mass., May 18, 2012 /- Boston Scientific Corporation (NYSE: BSX ) announces that seven abstracts and additional clinical data analyses will be presented at Digestive Disease Week ® (DDW), May 19 – 22 in San Diego. The analyses involve the SpyGlass ® Direct Visualization System, WallFlex® Biliary RX Stent, Expect™ 19 Flex Endoscopic Ultras...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Ocera Therapeutics receives CE Mark for Zysaâ„¢ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
SAN DIEGO, May 18, 2012 /- Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa™ (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a c...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
SAN DIEGO, May 18, 2012 /- Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
MORRISTOWN, N.J., May 18, 2012 /- Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip® XL. Actavis believes this is the first generic Requip® XL available in the US. Distribution...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
STAMFORD, Conn., May 18, 2012 /- Purdue Pharma L.P. will present an analysis of data from completed clinical trials for Butrans ® (buprenorphine) Transdermal System CIII at the American Pain Society's (APS) 31st Annual Scientific Meeting. The analysis includes an evaluation of supplemental analgesic use and pain scores across the 7-day dosing interval. (Logo: http://ph...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Watson Confirms Lo Loestrin® Fe Patent Challenge
PARSIPPANY, N.J., May 18, 2012 /- Watson Pharmaceuticals, Inc. (NYSE: WPI ) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and Ferrous Fumarate Tablets,1 mg/0.01 mg and ...
Please login or register to Read Full Article
Last Updated (Tuesday, 30 November 1999 00:00) 18 May 2012
Features Technology Articles
- Generex Augments Antigen Express Scientific Advisory Board - 18.05.12
- UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 - 18.05.12
- Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students - 18.05.12
- Swiss Engineering for Surgical Perfection - 18.05.12
- Medical Device Developers - Network at MD&M East Next Week - 18.05.12
- Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference - 18.05.12
- Denton Vacuum's New Website Organizes Thin-Film Technology Information By Industry - 18.05.12
- Pennsylvania DEP Announces X-ray Registration Fee Amnesty Program - 18.05.12
- Elsevier / Gold Standard's Kay Morgan Awarded NCPCP Highest Honor - 18.05.12
- Rural Health-Systems Benefit From Remote Pharmacy Technician Supervision - 18.05.12
You are browsing all Technology articles
Most Popular News
- New Route For 'existing Specialists' To Gain Entry Onto The Specialist Register Opens, UK
- New Mexico House Passes New Electronic Medical Records Law To Ensure Patient Privacy
- Grant Received By Boston University School Of Medicine To Focus On Medical School Curriculum Development In Armenia
- Kaiser Ordered To Pay $11.4 Million To Radiologist In Retaliation Case
- ICR Expands Elearning Offering, UK
- Over 3,000 Health Care Professionals Go On-line To Benefit From Parkinson's Awareness Training
Medical Search
Login
Who's Online
We have 96 guests onlinePolls
Medical Blog Directory
